Pomanda estimates the enterprise value of ENTERPRISE THERAPEUTICS LTD at £0 based on a Turnover of £0 and 1.17x industry multiple (adjusted for size and gross margin).
enterprise therapeutics ltdEstimated Valuation
£0
Pomanda estimates the enterprise value of ENTERPRISE THERAPEUTICS LTD at £0 based on an EBITDA of £-4.7m and a 4.66x industry multiple (adjusted for size and gross margin).
enterprise therapeutics ltdEstimated Valuation
£0
Pomanda estimates the enterprise value of ENTERPRISE THERAPEUTICS LTD at £0 based on Net Assets of £-5.8m and 1.59x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Enterprise Therapeutics LtdOverview
Enterprise Therapeutics Ltd is a live company located in brighton, BN1 9SB with a Companies House number of 09022750. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in May 2014, it's largest shareholder is
enterprise therapeutics holdings limited
with a 100% stake. Enterprise Therapeutics Ltd is a established,
unknown sized company, Pomanda has estimated its turnover at
£0 with
declining
growth in recent years.
There is insufficient data available to calculate a health check for Enterprise Therapeutics Ltd. Company Health Check FAQs
Health Rating0out of 5
0 Strong
0 Regular
5 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Enterprise Therapeutics Ltd
- - Industry AVG
Growth
3 year (CAGR) sales growth of -100%, show it is growing at a slower rate (13.1%)
- - Enterprise Therapeutics Ltd
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Enterprise Therapeutics Ltd
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Enterprise Therapeutics Ltd
- - Industry AVG
Employees
with 10 employees, this is below the industry average (54)
- - Enterprise Therapeutics Ltd
- - Industry AVG
Pay Structure
on an average salary of £185.5k, the company has a higher pay structure (£83k)
- - Enterprise Therapeutics Ltd
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- - Enterprise Therapeutics Ltd
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Enterprise Therapeutics Ltd
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Enterprise Therapeutics Ltd
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Enterprise Therapeutics Ltd
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 8 weeks, this is less cash available to meet short term requirements (30 weeks)
- - Enterprise Therapeutics Ltd
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 294.4%, this is a higher level of debt than the average (53.1%)
- - Enterprise Therapeutics Ltd
- - Industry AVG
ENTERPRISE THERAPEUTICS LTD financials
EXPORT
Enterprise Therapeutics Ltd's latest turnover from December 2023 is 0 and the company has net assets of -£5.8 million. According to their latest financial statements, Enterprise Therapeutics Ltd has 10 employees and maintains cash reserves of £1.5 million as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
May 2016
May 2015
Turnover
42,994
1,225,413
1,077,612
837,381
90,968
83,168
Other Income Or Grants
Cost Of Sales
39,188
1,238,939
1,069,549
423,314
44,797
42,634
Gross Profit
3,806
-13,526
8,063
414,067
46,171
40,534
Admin Expenses
4,665,233
4,761,566
5,342,314
7,211,710
10,042,905
6,276,386
3,982,347
1,954,503
2,096,591
267,068
Operating Profit
-4,665,233
-4,757,760
-5,355,840
-7,203,647
-9,628,838
-6,230,215
-3,941,813
-1,954,503
-2,096,591
-267,068
Interest Payable
1,109
2,356
1,827
2,719
2,807
402
1,437
953
999
Interest Receivable
21,972
2,039
693
14,483
75,749
17,039
15
108
409
Pre-Tax Profit
-4,644,370
-4,758,077
-5,356,974
-7,191,883
-9,555,896
-6,213,578
-3,943,235
-1,955,348
-2,097,590
-266,659
Tax
756,527
959,993
1,167,185
1,328,615
1,928,706
1,252,385
1,614,598
49,500
Profit After Tax
-3,887,843
-3,798,084
-4,189,789
-5,863,268
-7,627,190
-4,961,193
-2,328,637
-1,905,848
-2,097,590
-266,659
Dividends Paid
Retained Profit
-3,887,843
-3,798,084
-4,189,789
-5,863,268
-7,627,190
-4,961,193
-2,328,637
-1,905,848
-2,097,590
-266,659
Employee Costs
1,854,840
1,762,674
1,906,982
1,634,969
1,343,763
1,085,313
641,570
211,378
53,428
Number Of Employees
10
10
9
9
8
7
5
3
2
1
EBITDA*
-4,660,723
-4,754,190
-5,350,238
-7,195,247
-9,618,697
-6,223,018
-3,936,897
-1,952,130
-2,092,734
-266,813
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
May 2016
May 2015
Tangible Assets
16,916
4,714
3,349
8,251
15,366
20,179
12,124
16,845
15,506
15,045
Intangible Assets
Investments & Other
8,593
1
1
Debtors (Due After 1 year)
Total Fixed Assets
16,916
4,714
3,349
8,251
15,366
20,179
12,124
16,845
15,506
15,045
Stock & work in progress
Trade Debtors
4,621
405,269
1,922,412
1,293,233
836,344
Group Debtors
40
3,049,157
Misc Debtors
1,447,702
1,122,066
1,578,514
348,228
601,898
429,002
131,291
261,516
237,549
221,690
Cash
1,501,571
328,659
1,637,365
1,821,342
2,508,323
11,086,173
1,181,768
1,622,726
1,718,858
3,629,617
misc current assets
total current assets
2,949,273
1,450,725
3,220,540
7,018,901
5,032,633
12,808,408
2,149,403
1,884,242
1,956,407
3,851,307
total assets
2,966,189
1,455,439
3,223,889
7,027,152
5,047,999
12,828,587
2,161,527
1,901,087
1,971,913
3,866,352
Bank overdraft
Bank loan
Trade Creditors
957,609
25,297
435,394
227,497
487,193
653,935
279,237
144,820
362,272
18,078
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
7,774,900
3,308,619
868,888
690,259
582,889
569,546
175,786
119,300
36,074
177,117
total current liabilities
8,732,509
3,333,916
1,304,282
917,756
1,070,082
1,223,481
455,023
264,120
398,346
195,195
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
total liabilities
8,732,509
3,333,916
1,304,282
917,756
1,070,082
1,223,481
455,023
264,120
398,346
195,195
net assets
-5,766,320
-1,878,477
1,919,607
6,109,396
3,977,917
11,605,106
1,706,504
1,636,967
1,573,567
3,671,157
total shareholders funds
-5,766,320
-1,878,477
1,919,607
6,109,396
3,977,917
11,605,106
1,706,504
1,636,967
1,573,567
3,671,157
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
May 2016
May 2015
Operating Activities
Operating Profit
-4,665,233
-4,757,760
-5,355,840
-7,203,647
-9,628,838
-6,230,215
-3,941,813
-1,954,503
-2,096,591
-267,068
Depreciation
4,510
3,570
5,602
8,400
10,141
7,197
4,916
2,373
3,857
255
Amortisation
Tax
756,527
959,993
1,167,185
1,328,615
1,928,706
1,252,385
1,614,598
49,500
Stock
Debtors
325,636
-461,109
-2,219,479
1,278,344
802,075
754,600
706,119
39,826
15,859
221,690
Creditors
932,312
-410,097
207,897
-259,696
-166,742
374,698
134,417
126,742
344,194
18,078
Accruals and Deferred Income
4,466,281
2,439,731
178,629
107,370
13,343
393,760
56,486
-57,817
-141,043
177,117
Deferred Taxes & Provisions
Cash flow from operations
1,168,761
-1,303,454
-1,577,048
-7,297,302
-8,645,465
-4,956,775
-2,837,515
-1,873,531
-1,905,442
-293,308
Investing Activities
capital expenditure
-16,712
-4,935
-700
-1,285
-5,328
-15,252
-195
-4,173
-4,318
-15,300
Change in Investments
8,593
-1
1
cash flow from investments
-25,305
-4,934
-700
-1,286
-5,328
-15,252
-195
-4,173
-4,318
-15,300
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
7,994,747
1
14,859,795
2,398,174
-128,342
3,937,816
interest
20,863
-317
-1,134
11,764
72,942
16,637
-1,422
-845
-999
409
cash flow from financing
20,863
-317
-1,134
8,006,511
72,943
14,876,432
2,396,752
-129,187
-999
3,938,225
cash and cash equivalents
cash
1,172,912
-1,308,706
-183,977
-686,981
-8,577,850
9,904,405
-440,958
-2,006,891
-1,910,759
3,629,617
overdraft
change in cash
1,172,912
-1,308,706
-183,977
-686,981
-8,577,850
9,904,405
-440,958
-2,006,891
-1,910,759
3,629,617
enterprise therapeutics ltd Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for enterprise therapeutics ltd. Get real-time insights into enterprise therapeutics ltd's credit score, group structure and payment trends.
Perform a competitor analysis for enterprise therapeutics ltd by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other established companies, companies in BN1 area or any other competitors across 12 key performance metrics.
enterprise therapeutics ltd Ownership
ENTERPRISE THERAPEUTICS LTD group structure
Enterprise Therapeutics Ltd has no subsidiary companies.
Ultimate parent company
ENTERPRISE THERAPEUTICS LTD
09022750
ENTERPRISE THERAPEUTICS LTD Shareholders
The sole shareholder of Enterprise Therapeutics Ltd is Enterprise Therapeutics Holdings Limited.
enterprise therapeutics holdings limited
100%
enterprise therapeutics ltd directors
Enterprise Therapeutics Ltd currently has 2 directors.
The longest serving directors include
Dr John Ford (Nov 2016) and
Mr John Ford (Nov 2016).
72110 - Research and experimental development on biotechnology
incorporation date
May 2014
age
11
incorporated
UK
ultimate parent company
None
accounts
Full Accounts
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
JAMES COWPER KRESTON AUDIT
address
sussex innovation centre, science park square, brighton, BN1 9SB
Bank
-
Legal Advisor
-
enterprise therapeutics ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to enterprise therapeutics ltd. Currently there are 0 open charges and 1 have been satisfied in the past.
enterprise therapeutics ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ENTERPRISE THERAPEUTICS LTD. This can take several minutes, an email will notify you when this has completed.
enterprise therapeutics ltdCompanies House Filings - See Documents
